Stock Analysis
AbbVie Inc. (ABBV) Stock Analysis
AbbVie Inc. (ABBV) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
AbbVie Inc. (ABBV) currently has an AIQ Score of 56/100, indicating a neutral setup. Sentiment is the strongest factor at 86/100. Value is the weakest current factor at 36/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
ABBV at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $284.80 |
| AIQ Score | 56/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $459.35B |
| P/E Ratio (TTM) | 73.25 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | $2.04 |
| Revenue (quarter ended 2026-06-30) | $16.99B |
| Dividend Yield (TTM) | 2.63% |
| Beta | 0.28 |
| Volume | 4.39M |
| 52-week range | $190.75-$291.40 |
| RSI 14 | 73.65 |
| 50-Day SMA | $264.70 |
| 200-Day SMA | $234.84 |
| Analyst Price Target | $287.46 |
| Next Earnings | Oct 30, 2026 |
ABBVAbbVie Inc.
Healthcare / Drug Manufacturers - General
Low Priority
Above Peers
Latest quote
- Momentum82
- Value36
- Quality60
- Risk resilience44
- Sentiment86
ABBV Stock Analysis Summary
AbbVie Inc. (ABBV) currently has an AIQ Score of 56/100, indicating a neutral setup. Sentiment is the strongest factor at 86/100. Value is the weakest current factor at 36/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, ABBV has AIQ Score of 56/100 with Sentiment base of 86/100 and fading Value at 36/100. Wait for component alignment before adding exposure.
Sentiment (86/100) leads while Value (36/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -1.48% stock move · ABBV classified in Drug Manufacturers - General.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is ABBV Bullish or Bearish Right Now?
ABBV currently has a neutral overall setup. Sentiment is the strongest factor at 86/100, while Value is weakest at 36/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 60/100.
- - Momentum is constructive at 82/100.
- - Price is +7.59% above its 50-day SMA.
- - Analyst target implies +0.93% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (35 vs 5).
- - Value is the current constraint at 36/100.
- - Risk Resilience is weak at 44/100.
Current Consensus
ABBV's Technical Analysis Consensus is currently Strong Buy, with 35 buy, 5 neutral, and 5 sell votes. ABBV's 14-day RSI is 73.65, which places the stock in an overbought momentum range. ABBV's beta is 0.28, indicating lower market sensitivity than the broad market.
What Changed in ABBV?
The largest recent change in ABBV is Momentum moving down by 1.0 points over the available 7-day comparison window. Sentiment remains the strongest visible factor.
What Would Change the ABBV Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
ABBV Decision Framework
Public evidence layers, setup checks, and risk context for AbbVie Inc..
AbbVie Inc. (ABBV) Stock Analysis
AbbVie Inc. has an AIQ Score of 56/100 in a Neutral regime. Sentiment is strongest at 86/100. Beta is 0.28, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | ABBV is in a Neutral AIQ regime with score 56/100. |
| Signal Conflict | The primary conflict is that sentiment leads at 86/100 while value lags at 36/100. |
| Factor Evidence | Momentum 82/100 · Value 36/100 · Quality 60/100 · Risk 44/100 · Sentiment 86/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Sentiment is the strongest factor at 86/100.
Momentum is 82/100 and RSI (14) is 73.6.
ABBV is in a Neutral regime at 56/100.
Risk factor is 44/100 with beta 0.28 and annual volatility 25.89%.
Current conflict: sentiment leads at 86/100 while value lags at 36/100.
ABBV Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
ABBV Fundamentals
ABBV valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
ABBV Technical Analysis
ABBV technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
ABBV Stock Catalysts
Track ABBV earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
ABBV Dividend Analysis
ABBV dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
ABBV Financial Data
ABBV revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
ABBV Risk Analysis
ABBV volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
ABBV Stock News
ABBV stock news, market tone, recent headlines, and catalyst context.
ABBV vs Large-Cap Pharma Peers
Current peer cohort: ABBV · JNJ · PFE · MRK · LLY. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| ABBV Current stock | 56/100 | 36/100 | 82/100 | 44/100 | 0.77 | 25.89% | Current |
| JNJ Johnson & Johnson | 52/100 | 39/100 | 48/100 | 48/100 | 1.31 | 20.43% | ABBV vs JNJ |
| PFE Pfizer | 64/100 | 67/100 | 79/100 | 54/100 | 0.81 | 21.51% | ABBV vs PFE |
| MRK Merck | 47/100 | 27/100 | 71/100 | 44/100 | 1.88 | 29.63% | ABBV vs MRK |
| LLY Eli Lilly | 62/100 | 26/100 | 95/100 | 50/100 | 1.36 | 34.89% | ABBV vs LLY |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 21, 2026.
Popular ABBV Comparisons
How ABBV scores against the names it is most often compared with.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts3 recent quarterly periods are available for review.
Checked Oct 21, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching ABBV
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for ABBV
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
ABBV Stock FAQ
What is ABBV stock price today?
AbbVie Inc.'s current stock price is $284.80. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is ABBV bullish or bearish right now?
ABBV's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is ABBV's market cap?
ABBV's market cap is $459.35B based on the latest completed market-close snapshot from Oct 21, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is ABBV's current P/E ratio?
ABBV's current P/E ratio is 73.25 based on the latest completed market-close snapshot from Oct 21, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is ABBV's RSI?
ABBV's 14-day RSI is 73.65 based on the latest completed market-close snapshot from Oct 21, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is ABBV above its 50-day and 200-day moving averages?
ABBV is 7.59% from its 50-day SMA and 21.27% from its 200-day SMA based on the latest completed market-close snapshot from Oct 21, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is ABBV's next earnings date?
ABBV's next earnings date is currently listed as Oct 30, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does ABBV pay a dividend?
ABBV's dividend yield is 2.63% based on the latest completed market-close snapshot from Oct 21, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.